<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00787813</url>
  </required_header>
  <id_info>
    <org_study_id>NAC after cerclage</org_study_id>
    <nct_id>NCT00787813</nct_id>
  </id_info>
  <brief_title>N-Acetyl Cysteine After Cervical Cerclage</brief_title>
  <acronym>NAC-CC</acronym>
  <official_title>Effect of Oral N-Acetyl Cysteine on Pregnancy Outcome After Cervical Cerclage: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the effect of N-acetyl cysteine (NAC) on pregnancy
      outcome in women undergoing cervical cerclage for cervical insufficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized controlled clinical trial to be carried out in a university-affiliated tertiary
      center.Participating women will be randomized into two groups: Group A will be given an oral
      daily dose of 0.6 g of NAC in effervescent form; group B, serving as controls, will not
      receive NAC.The two groups will then be compared according to pregnancy outcome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gestational age at delivery</measure>
    <time_frame>3-6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Take home babies, neonatal morbidity</measure>
    <time_frame>3-6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cervical Cerclage</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N-Acetyl Cysteine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-Acetyl Cysteine</intervention_name>
    <description>oral daily dose of 0.6 g of N-acetyl cysteine in effervescent form</description>
    <arm_group_label>1</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women with history suggestive of cervical insufficiency together with ultrasound
             findings suggestive of cervical insufficiency undergoing elective cervical cerclage
             between the 11th and 12th gestational week.

          -  singelton viable fetus

        Exclusion Criteria:

          -  women tested positive for bacterial vaginosis

          -  women currently with threatened abortion (vaginal bleeding or uterinecramps)

          -  age older than 35 years or younger than 20 years

          -  unwillingness to participate

          -  irregular and/or uncertain menstrual dates

          -  rupture of membranes

          -  previous cesarean delivery

          -  possible risks for preterm birth in the current or previous pregnancy such as twin
             pregnancy, IUFD, malpresentation, known fetal anomaly, progesterone or heparin
             treatment during the current pregnancy, hypertension, and/or seizure disorders.

          -  women with contra indications for cervical cerclage or anesthesia.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AHMED M NASR, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women's Health Center, Assiut University, EGYPT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Women's Health Center</name>
      <address>
        <city>Assiut</city>
        <zip>71516</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Shahin AY, Hassanin IM, Ismail AM, Kruessel JS, Hirchenhain J. Effect of oral N-acetyl cysteine on recurrent preterm labor following treatment for bacterial vaginosis. Int J Gynaecol Obstet. 2009 Jan;104(1):44-8. doi: 10.1016/j.ijgo.2008.08.026. Epub 2008 Oct 11.</citation>
    <PMID>18851855</PMID>
  </reference>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2008</study_first_submitted>
  <study_first_submitted_qc>November 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2008</study_first_posted>
  <last_update_submitted>November 19, 2008</last_update_submitted>
  <last_update_submitted_qc>November 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. Ezat Hamed Sayed</name_title>
    <organization>Department of Obstetrics &amp; Gynecology</organization>
  </responsible_party>
  <keyword>N-acetyl cysteine (NAC)</keyword>
  <keyword>Cervical cerclage</keyword>
  <keyword>cervical cerclage for cervical insufficiency</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

